Enabling functionality and translation fidelity characterization of mRNA-based vaccines with a platform-based, antibody-free mass spectrometry detection approach
Alyssa Q. StivingiD, Benjamin W. RooseiD, Christopher M. TubbsiD, Mark A. Haverick, Ashley Gruber, Richard R. RustandiiD, Jesse L. Kuiper, Matthew W. SchombsiD, Hillary A. Schuessler, Xuanwen LiiD
Abstract
The success of mRNA-based therapeutics and vaccines can be attributed to their rapid development, adaptability to new disease variants, and scalable production. Modified ribonucleotides are often used in mRNA-based vaccines or therapeutics to enhance stability and reduce immunogenicity. However, substituting uridine with N1-methylpseudouridine has recently been shown to result in +1 ribosomal frameshifting that induces cellular immunity to the translated off-target protein. To accelerate vaccine development, it is critical to have analytical methods that can be rapidly brought online to assess the functionality and translation fidelity of mRNA constructs. Here, a platform-based, antibody-free method was developed using cell-free translation (CFT) and liquid chromatography-tandem mass spectrometry (MS) that can detect, characterize, and provide relative quantification of antigen proteins translated from mRNA vaccine drug substance. This workflow enabled the evaluation of mRNA subjected to thermal stress as well as bivalent (i.e., two mRNA encoding different antigen variants) drug substance. Additionally, the MS detection approach exhibited high sensitivity and specificity by accurately identifying all six translated proteins and their relative abundances in a dose-dependent manner following transfection of human cells with a hexavalent mRNA mixture encapsulated in lipid nanoparticles (LNPs), despite significant protein sequence homology. Expanding on these efforts, we show the utility of the CFT-MS approach in identifying the presence and junction of +1 ribosomal frameshifting resulting from N1-methylpseudouridation. Overall, this CFT-MS methodology offers a valuable analytical tool for the development and production of mRNA-based vaccines by facilitating the evaluation of mRNA quality and functionality while ensuring accurate translation of antigen proteins. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=91 SRC="FIGDIR/small/594137v1_ufig1.gif" ALT="Figure 1"> View larger version (19K): org.highwire.dtl.DTLVardef@e4c7a7org.highwire.dtl.DTLVardef@1efddd1org.highwire.dtl.DTLVardef@cbfcbaorg.highwire.dtl.DTLVardef@1ae1acc_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 15
- FWCI
- 3.60
- Field percentile
- top 6%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Analytical evaluation of eukaryotic cell-free translation (CFT) systems to assess mRNA translatability
Benjamin W. Roose, Pankaj Dwivedi, Matthew W. Schombs·bioRxiv·Sep 11, 2026
- Development and application of an uncapped mRNA platform
- Multi-attribute characterisation of mRNA via MazF endoribonuclease and LC-MS workflows
Emma P Welbourne, Gareth R. Owen, … Mark J. Dickman·bioRxiv·Sep 24, 2026
- Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations
R. Y. Gao, C. M. Riley, … E. D. Dawson·bioRxiv·Aug 31, 2022
- Single Platform Solution for Identity and Quantification of Influenza Hemagglutinin (HA) mRNA Constructs and Resulting Expressed Proteins for Application to Influenza mRNA Vaccines
Rachel Y. Gao, Tianjing Hu, … Erica D. Dawson·bioRxiv·Feb 7, 2026
- Characterisation and sequence mapping of large RNA and mRNA therapeutics using mass spectrometry
C. Vanhinsbergh, A. Criscuolo, … M. J. Dickman·bioRxiv·Feb 14, 2022